Related Experiment Video

Updated: Apr 5, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K

Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias

Maria Rosaria Ricciardi1, Simone Mirabilii2, Matteo Allegretti2

  • 1Hematology, "Sant'Andrea" Hospital-Sapienza, University of Rome, Department of Clinical and Molecular Medicine, Rome, Italy;

Blood
|August 16, 2015
PubMed

Insights

The novel CPT1a inhibitor ST1326 effectively halts leukemia cell growth by blocking fatty acid oxidation (FAO). This metabolic targeting shows promise for treating hematologic malignancies, including acute myeloid leukemia.

Area of Science:

  • Biochemistry
  • Oncology
  • Metabolic pathways

Background:

  • Cancer cells exhibit altered metabolic processes.
  • Fatty acid oxidation (FAO) serves as a crucial carbon source for tumor anabolism.
  • Carnitine palmitoyl transferase 1a (CPT1a) regulates the rate-limiting step in FAO.

Purpose of the Study:

  • To investigate the in vitro antileukemic activity of the novel CPT1a inhibitor, ST1326.
  • To assess the impact of ST1326 on leukemia cell lines and primary patient cells.

Main Methods:

  • Real-time metabolic analysis to monitor FAO.
  • Treatment of leukemia cell lines and primary hematopoietic malignant cells with ST1326.
  • Assessment of cell growth, mitochondrial function, and apoptosis.

Main Results:

  • ST1326 significantly inhibited FAO in leukemia cells.
  • Observed dose- and time-dependent cell growth arrest, mitochondrial damage, and apoptosis induction.
  • ST1326 demonstrated cytotoxic activity against primary acute myeloid leukemia cells.

Conclusions:

  • Targeting metabolic processes, specifically FAO, is a viable therapeutic strategy for leukemia.
  • The CPT1a inhibitor ST1326 exhibits potent in vitro antileukemic effects.
  • Further investigation into ST1326 for hematologic malignancy treatment is warranted.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

922
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.6K